Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Chan, Arlene; Moy, Beverly; Mansi, Janine; Ejlertsen, Bent; Holmes, Frankie; Chia, Stephen; Iwata, Hiroji; Gnant, Michael; Loibl, Sibylle; Barrios, Carlos; Somali, Isil; Smichkoska, Snezhana; Martinez, Noelia; Alonso, Mirta; Link, John; Mayer, Ingrid; Cold, Soren; Murillo, Serafin; Senecal, Francis; Inoue, Kenichi; Ruiz-Borrego, Manuel; Hui, Rina; Denduluri, Neelima; Patt, Debra; Rugo, Hope; Johnston, Stephen; Bryce, Richard; Zhang, Bo; Xu, Feng; Wong, Alvin; Martin, Miguel

doi:10.1016/j.clbc.2020.09.014

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Chan A., Moy B., Mansi J., Ejlertsen B., Holmes F. A., Chia S., ...Daha Fazla

CLINICAL BREAST CANCER, cilt.21, sa.1, ss.80-98, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 1
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.clbc.2020.09.014
Dergi Adı: CLINICAL BREAST CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.80-98
Anahtar Kelimeler: Adjuvant therapy, Disease-free survival, Distant disease-free survival, Neoadjuvant therapy, Overall survival
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

In the patient population with early-stage human epidermal growth factor receptor 2-positive/hormone receptor-positive breast cancer who initiate neratinib within 1 year of trastuzumab-based therapy, the absolute 5-year invasive disease-free survival benefit versus placebo is 5.1%, and absolute 8-year overall survival benefit is 2.1%. Among those with residual disease after neoadjuvant therapy (non-pathologic complete response), absolute gains with neratinib are 7.4% and 9.1%, respectively.